QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:CEMI

Chembio Diagnostics - CEMI Stock Forecast, Price & News

$0.38
+0.01 (+2.70%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.38
▼
$0.41
50-Day Range
$0.29
▼
$0.45
52-Week Range
$0.19
▼
$1.24
Volume
1.25 million shs
Average Volume
692,802 shs
Market Capitalization
$13.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CEMI stock logo

About Chembio Diagnostics (NASDAQ:CEMI) Stock

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

March 22, 2023 | americanbankingnews.com
Chembio Diagnostics (NASDAQ:CEMI) Now Covered by Analysts at StockNews.com
March 21, 2023 | finance.yahoo.com
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023
March 22, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 15, 2023 | finance.yahoo.com
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
March 15, 2023 | finance.yahoo.com
Chembio Announces Letter to Stockholders Regarding Tender Offer
March 14, 2023 | americanbankingnews.com
Chembio Diagnostics (NASDAQ:CEMI) Receives New Coverage from Analysts at StockNews.com
February 24, 2023 | finance.yahoo.com
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
February 8, 2023 | benzinga.com
Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm
March 22, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
February 2, 2023 | wsj.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. Buyout
February 1, 2023 | finance.yahoo.com
French Rapid Testing Company Scoops Up Chembio Diagnostics For $17M
January 31, 2023 | finance.yahoo.com
Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement
January 21, 2023 | seekingalpha.com
CEMI Chembio Diagnostics, Inc.
January 7, 2023 | forbes.com
Chembio Diagnostics
November 28, 2022 | finance.yahoo.com
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
November 6, 2022 | seekingalpha.com
Chembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call Transcript
November 3, 2022 | finance.yahoo.com
Chembio Diagnostics Reports Third Quarter 2022 Financial Results
October 20, 2022 | finance.yahoo.com
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
September 6, 2022 | finance.yahoo.com
Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay
September 3, 2022 | finance.yahoo.com
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
August 16, 2022 | finance.yahoo.com
Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off
August 16, 2022 | finance.yahoo.com
Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development
August 4, 2022 | finance.yahoo.com
Chembio Diagnostics Reports Second Quarter 2022 Financial Results
July 21, 2022 | finance.yahoo.com
Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022
June 15, 2022 | baystreet.ca
Chembio Expands Distribution
June 15, 2022 | finance.yahoo.com
Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel
May 17, 2022 | seekingalpha.com
Chembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facility
See More Headlines
Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Company Calendar

Last Earnings
11/04/2021
Today
3/22/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CEMI
CUSIP
N/A
CIK
1092662
Web
www.chembio.com
Phone
(631) 924-1135
Fax
631-924-2065
Employees
337
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,900,000.00
Net Margins
-60.93%
Pretax Margin
-60.91%
Return on Equity
-129.14%
Return on Assets
-50.01%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.22
Quick Ratio
1.00

Sales & Book Value

Annual Sales
$47.82 million
Price / Sales
0.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
0.34

Miscellaneous

Outstanding Shares
36,710,000
Free Float
35,497,000
Market Cap
$14.39 million
Optionable
Not Optionable
Beta
1.83

Key Executives

  • Richard L. Eberly
    President, Chief Executive Officer & Director
  • Paul J. Angelico
    Chief Operations Officer & Executive VP
  • Lawrence J. Steenvoorden
    Chief Financial Officer, Secretary & Executive VP
  • Javan Esfandiari
    Executive VP, Chief Science & Technology Officer
  • Paul Lambotte
    Vice President-Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













CEMI Stock - Frequently Asked Questions

Should I buy or sell Chembio Diagnostics stock right now?

0 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently for the stock. The consensus among Wall Street research analysts is that investors should "n/a" CEMI shares.
View CEMI analyst ratings or view top-rated stocks.

How have CEMI shares performed in 2023?

Chembio Diagnostics' stock was trading at $0.2197 at the beginning of 2023. Since then, CEMI shares have increased by 78.4% and is now trading at $0.3920.
View the best growth stocks for 2023 here.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 876,600 shares, a decrease of 34.6% from the February 13th total of 1,340,000 shares. Based on an average trading volume of 565,400 shares, the days-to-cover ratio is currently 1.6 days.
View Chembio Diagnostics' Short Interest.

When is Chembio Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our CEMI earnings forecast.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) posted its earnings results on Thursday, November, 4th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.05. The business earned $12.06 million during the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 129.14% and a negative net margin of 60.93%. During the same quarter last year, the firm posted ($0.28) EPS.

What other stocks do shareholders of Chembio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $0.39.

How much money does Chembio Diagnostics make?

Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $14.39 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

The company employs 337 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.

This page (NASDAQ:CEMI) was last updated on 3/22/2023 by MarketBeat.com Staff